XORTX Therapeutics (XRTX)
(Delayed Data from NSDQ)
$2.59 USD
-0.31 (-10.75%)
Updated Apr 25, 2024 03:51 PM ET
After-Market: $2.64 +0.05 (1.93%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for XORTX Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 3 | 11 | 15 | 0 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | NA | 0 | 0 | 0 | NA |
Inventories | NA | 0 | 0 | 0 | NA |
Other Current Assets | 1 | 0 | 1 | 1 | NA |
Total Current Assets | 4 | 11 | 16 | 2 | NA |
Net Property & Equipment | 0 | 0 | 0 | 0 | NA |
Investments & Advances | NA | 0 | 0 | 0 | NA |
Other Non-Current Assets | NA | 0 | 0 | 0 | NA |
Deferred Charges | NA | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 1 | 1 | 1 | 0 | NA |
Total Assets | 5 | 13 | 18 | 2 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | NA |
Accounts Payable | 0 | 2 | 1 | 1 | NA |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | NA | 0 | 0 | 0 | NA |
Income Taxes Payable | NA | 0 | 0 | 0 | NA |
Other Current Liabilities | NA | 0 | 0 | 0 | NA |
Total Current Liabilities | 0 | 2 | 1 | 1 | NA |
Mortgages | NA | 0 | 0 | 0 | NA |
Deferred Taxes/Income | NA | 0 | 0 | 0 | NA |
Convertible Debt | NA | 0 | 0 | 0 | NA |
Long-Term Debt | NA | 0 | 0 | 0 | NA |
Non-Current Capital Leases | NA | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 1 | 4 | 4 | 0 | NA |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | NA |
Total Liabilities | 1 | 6 | 4 | 1 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | NA |
Common Stock (Par) | 17 | 16 | 16 | 6 | NA |
Capital Surplus | NA | 0 | 0 | 0 | NA |
Retained Earnings | -18 | -15 | -8 | -6 | NA |
Other Equity | 5 | 6 | 5 | 1 | NA |
Treasury Stock | NA | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 5 | 7 | 13 | 1 | NA |
Total Liabilities & Shareholder's Equity | 5 | 13 | 18 | 2 | NA |
Total Common Equity | 100,004 | 7 | 13 | 1 | 0 |
Shares Outstanding | 2.00 | 1.60 | 1.40 | NA | NA |
Book Value Per Share | 50,001.82 | 4.55 | 9.54 | 0.00 | 0.00 |
Fiscal Year End for XORTX Therapeutics Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,996 | 5 | 6 | 8 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | NA | 0 | 0 | 0 |
Inventories | NA | NA | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 0 | 0 | 0 |
Total Current Assets | NA | 4 | 5 | 6 | 8 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | NA | 0 | 0 | 0 |
Other Non-Current Assets | NA | NA | 0 | 0 | 0 |
Deferred Charges | NA | NA | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 1 | 1 |
Total Assets | NA | 5 | 7 | 8 | 10 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 0 | 0 | 0 |
Accounts Payable | NA | 0 | 1 | 0 | 1 |
Current Portion Long-Term Debt | NA | NA | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | NA | 0 | 0 | 0 |
Income Taxes Payable | NA | NA | 0 | 0 | 0 |
Other Current Liabilities | NA | NA | 0 | 0 | 0 |
Total Current Liabilities | NA | 0 | 1 | 0 | 1 |
Mortgages | NA | NA | 0 | 0 | 0 |
Deferred Taxes/Income | NA | NA | 0 | 0 | 0 |
Convertible Debt | NA | NA | 0 | 0 | 0 |
Long-Term Debt | NA | NA | 0 | 0 | 0 |
Non-Current Capital Leases | NA | NA | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | NA | 0 | 0 | 0 |
Total Liabilities | NA | 1 | 1 | 0 | 1 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | 0 | 0 |
Common Stock (Par) | NA | 17 | 17 | 17 | 17 |
Capital Surplus | NA | NA | 0 | 0 | 0 |
Retained Earnings | NA | -18 | -21 | -19 | -18 |
Other Equity | NA | 5 | 10 | 10 | 10 |
Treasury Stock | NA | NA | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 5 | 6 | 7 | 9 |
Total Liabilities & Shareholder's Equity | NA | 5 | 7 | 8 | 10 |
Total Common Equity | 0 | 100,004 | 6 | 7 | 9 |
Shares Outstanding | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
Book Value Per Share | 0.00 | 50,001.82 | 3.05 | 3.70 | 4.53 |